MX2021001069A - Formas cristalinas de un inhibidor de lta4h. - Google Patents
Formas cristalinas de un inhibidor de lta4h.Info
- Publication number
- MX2021001069A MX2021001069A MX2021001069A MX2021001069A MX2021001069A MX 2021001069 A MX2021001069 A MX 2021001069A MX 2021001069 A MX2021001069 A MX 2021001069A MX 2021001069 A MX2021001069 A MX 2021001069A MX 2021001069 A MX2021001069 A MX 2021001069A
- Authority
- MX
- Mexico
- Prior art keywords
- crystalline forms
- disorders
- diseases
- lta4h
- lta4h inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
Abstract
Esta solicitud se refiere a diversas formas cristalinas del ácido (S)-3-amino-4-(5-(4-((5-cloro-3-fluoropiridin-2-il)oxi)fenil)-2H- tetrazol-2-il)butanoico en su forma libre, así como a composiciones, método de elaboración y métodos de uso de las mismas. En algunas formas de realización, las formas cristalinas también contienen agua ("hidratos"). Estos materiales son útiles en el tratamiento de enfermedades y trastornos que típicamente son aliviados por la inhibición de LTA4H. Tales enfermedades y trastornos pueden incluir trastornos inflamatorios y autoinmunes e inflamación pulmonar y de las vías respiratorias.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018000278 | 2018-07-31 | ||
| PCT/IB2019/056436 WO2020026108A1 (en) | 2018-07-31 | 2019-07-29 | Crystalline forms of a lta4h inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021001069A true MX2021001069A (es) | 2021-04-12 |
Family
ID=68072853
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021001069A MX2021001069A (es) | 2018-07-31 | 2019-07-29 | Formas cristalinas de un inhibidor de lta4h. |
| MX2024003339A MX2024003339A (es) | 2018-07-31 | 2021-01-27 | Formas cristalinas de un inhibidor de lta4h. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024003339A MX2024003339A (es) | 2018-07-31 | 2021-01-27 | Formas cristalinas de un inhibidor de lta4h. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11993582B2 (es) |
| EP (2) | EP3830081B1 (es) |
| JP (1) | JP7356496B2 (es) |
| KR (1) | KR20210038900A (es) |
| CN (1) | CN112513026A (es) |
| AR (1) | AR115866A1 (es) |
| AU (2) | AU2019315778C1 (es) |
| BR (1) | BR112021001435A2 (es) |
| CA (1) | CA3105542A1 (es) |
| CL (1) | CL2021000254A1 (es) |
| IL (1) | IL279953A (es) |
| MX (2) | MX2021001069A (es) |
| TW (2) | TWI810338B (es) |
| WO (1) | WO2020026108A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11932630B2 (en) | 2021-04-16 | 2024-03-19 | Novartis Ag | Heteroaryl aminopropanol derivatives |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4820723A (en) | 1987-08-14 | 1989-04-11 | Eli Lilly And Company | Disubstituted tetrazole leukotriene antagonists and methods for their use thereas |
| EP1534683A4 (en) | 2002-06-27 | 2005-08-24 | Nitromed Inc | CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHOD OF USE |
| CA2603122A1 (en) * | 2005-03-31 | 2006-10-05 | Janssen Pharmaceutica N.V. | Phenyl and pyridyl lta4h modulators |
| US20070078263A1 (en) * | 2005-09-21 | 2007-04-05 | Decode Chemistry, Inc. | Biaryl substituted heterocycle inhibitors of lta4h for treating inflammation |
| PL3456707T3 (pl) | 2007-11-06 | 2020-09-21 | Ptc Therapeutics, Inc. | Pochodne 4-(p-chinonylo)-2-hydroksybutanamidu do leczenia chorób mitochondrialnych |
| CR20160279A (es) * | 2013-12-20 | 2016-08-31 | Novartis Ag | Derivados de ácido heteroaril butanóico como inhibidores de lta4h |
-
2019
- 2019-07-29 MX MX2021001069A patent/MX2021001069A/es unknown
- 2019-07-29 EP EP19779099.1A patent/EP3830081B1/en active Active
- 2019-07-29 BR BR112021001435-7A patent/BR112021001435A2/pt unknown
- 2019-07-29 CN CN201980050149.1A patent/CN112513026A/zh active Pending
- 2019-07-29 TW TW108126714A patent/TWI810338B/zh active
- 2019-07-29 AR ARP190102132A patent/AR115866A1/es unknown
- 2019-07-29 WO PCT/IB2019/056436 patent/WO2020026108A1/en active Application Filing
- 2019-07-29 CA CA3105542A patent/CA3105542A1/en active Pending
- 2019-07-29 KR KR1020217005210A patent/KR20210038900A/ko unknown
- 2019-07-29 US US17/264,333 patent/US11993582B2/en active Active
- 2019-07-29 AU AU2019315778A patent/AU2019315778C1/en active Active
- 2019-07-29 JP JP2021504833A patent/JP7356496B2/ja active Active
- 2019-07-29 TW TW112126391A patent/TWI834581B/zh active
- 2019-07-29 EP EP24169420.7A patent/EP4389125A3/en active Pending
-
2021
- 2021-01-04 IL IL279953A patent/IL279953A/en unknown
- 2021-01-27 MX MX2024003339A patent/MX2024003339A/es unknown
- 2021-01-29 CL CL2021000254A patent/CL2021000254A1/es unknown
-
2022
- 2022-03-21 AU AU2022201921A patent/AU2022201921B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TW202035388A (zh) | 2020-10-01 |
| AU2019315778C1 (en) | 2022-07-07 |
| AU2022201921B2 (en) | 2023-08-03 |
| TWI834581B (zh) | 2024-03-01 |
| AU2019315778B2 (en) | 2022-01-13 |
| EP4389125A2 (en) | 2024-06-26 |
| EP3830081A1 (en) | 2021-06-09 |
| EP4389125A3 (en) | 2024-09-11 |
| WO2020026108A1 (en) | 2020-02-06 |
| BR112021001435A2 (pt) | 2021-04-27 |
| US11993582B2 (en) | 2024-05-28 |
| CN112513026A (zh) | 2021-03-16 |
| AU2022201921A1 (en) | 2022-04-14 |
| AR115866A1 (es) | 2021-03-03 |
| AU2019315778A1 (en) | 2021-01-28 |
| KR20210038900A (ko) | 2021-04-08 |
| TWI810338B (zh) | 2023-08-01 |
| EP3830081B1 (en) | 2024-05-22 |
| IL279953A (en) | 2021-03-01 |
| JP2021533111A (ja) | 2021-12-02 |
| JP7356496B2 (ja) | 2023-10-04 |
| US20210300897A1 (en) | 2021-09-30 |
| MX2024003339A (es) | 2024-04-05 |
| CL2021000254A1 (es) | 2021-08-20 |
| TW202342446A (zh) | 2023-11-01 |
| CA3105542A1 (en) | 2020-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019015580A (es) | Metodos para tratar la enfermedad de huntington. | |
| MX2019015578A (es) | Metodos para tratar la enfermedad de huntington. | |
| MX2020014315A (es) | Compuestos de heteroarilo para tratar la enfermedad de huntington. | |
| MX2020009956A (es) | Compuestos para el tratamiento de enfermedad de hungtinton. | |
| CR20210139A (es) | Compuestos de sulfonamidaurea novedosos | |
| AR082096A1 (es) | Derivados pirazolicos de carboxamida utiles para proteger plantas de fitoenfermedades y composiciones que los contienen | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| PH12015502012A1 (en) | Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis | |
| MX2019013561A (es) | Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos. | |
| RS52823B (en) | NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | |
| MX2010003612A (es) | Derivados de oxadiazol. | |
| EA201490357A1 (ru) | Индазолы | |
| BR112021023054A2 (pt) | Formas cristalinas de um inibidor de btk | |
| UA108645C2 (uk) | Композиція для боротьби з хворобами рослин і її застосування | |
| WO2010018109A3 (en) | Substituted aminotetralines | |
| EA201101695A1 (ru) | Усовершенствованный способ синтеза пирфенидона | |
| CR20200413A (es) | Inhibidores de canal de potencial de receptor transitorio de oxadiazol | |
| CR20210072A (es) | Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas | |
| TW200745066A (en) | Novel PTP1B inhibitors | |
| EA201171210A1 (ru) | Производные оксадиазола | |
| MX2012012328A (es) | Compuestos pirazol como inhibidores de jak. | |
| WO2015081349A3 (en) | Combination of novel nitrification inhibitors and herbicides as well as combination of (thio)phosphoric acid triamides and herbicides | |
| WO2012059442A3 (en) | Neurotrypsin inhibitors | |
| NZ605010A (en) | Novel calcium salts of compound as anti-inflammatory, immunomodulatory and anti-proliferatory agents | |
| PH12017501428A1 (en) | 4-substituted benzoxaborole compounds and uses thereof |